Form 8-K ARVINAS, INC. For: Apr 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Arvinas Inc. (ARVN) Enters License and Asset Agreement with Novartis
April 11, 2024 7:11 AM EDTOn April 10, 2024, Arvinas Inc. (NASDAQ: ARVN), entered into a transaction (the Transaction), including both a license agreement (the License Agreement) and an asset purchase agreement (the Asset Agreement), with Novartis Pharma AG (Novartis). Pursuant to the License Agreement, the Company will grant to Novartis an exclusive worldwide license for the development, manufacture and commercialization of ARV-766, the Companys second generation PROTAC® androgen receptor (AR) degrader for patients with prostate cancer. Pursuant to the Asset Agreement, the... More
